Law Firms Press Ardent Health Investors as March 9 Lead-Plaintiff Deadline Nears in Securities Case

The case remains in early stages in Tennessee federal court without a certified class.

Overview

Investors who bought Ardent Health shares between July 18, 2024 and November 12, 2025 have until March 9, 2026 to seek appointment as lead plaintiff.
Complaints allege Ardent overstated the collectability of accounts receivable by using a 180‑day cliff instead of relying on detailed reviews of historical collections.
Plaintiffs also claim the company misrepresented the sufficiency of its professional malpractice liability insurance.
On November 12, 2025, Ardent reported a $43 million revenue reduction tied to accounting estimate changes and a $54 million increase in professional liability reserves related to New Mexico claims, and the stock fell about 33.8% the next day to $9.30.
The consolidated action, Postiwala v. Ardent Health, Inc., cites Exchange Act Sections 10(b) and 20(a) and SEC Rule 10b‑5 and is pending in the U.S. District Court for the Middle District of Tennessee.